Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differentiation of atypical Parkinson syndromes.
Höglinger GU, Kassubek J, Csoti I, Ehret R, Herbst H, Wellach I, Winkler J, Jost WH. Höglinger GU, et al. Among authors: ehret r. J Neural Transm (Vienna). 2017 Aug;124(8):997-1004. doi: 10.1007/s00702-017-1700-4. Epub 2017 Feb 27. J Neural Transm (Vienna). 2017. PMID: 28243754 Review.
Parkinson's disease risk score: moving to a premotor diagnosis.
Winkler J, Ehret R, Büttner T, Dillmann U, Fogel W, Sabolek M, Winkelmann J, Kassubek J. Winkler J, et al. Among authors: ehret r. J Neurol. 2011 May;258(Suppl 2):S311-5. doi: 10.1007/s00415-011-5952-x. J Neurol. 2011. PMID: 21560061 Review.
Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole.
Eggert K, Öhlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH; In Cooperation With the German Competence Network on Parkinson’s Disease. Eggert K, et al. Among authors: ehret r. Clin Neuropharmacol. 2014 Jul-Aug;37(4):116-22. doi: 10.1097/WNF.0000000000000041. Clin Neuropharmacol. 2014. PMID: 24992083 Clinical Trial.
Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.
Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group. Trenkwalder C, et al. Among authors: ehret r. Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19. Lancet Neurol. 2015. PMID: 26494524 Clinical Trial.
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
67 results